Phase I pharmacology study of oral and intravenous BCX-1777 [forodesine] in patients with refractory T-cell and non-T-cell malignancies
Phase of Trial: Phase I
Latest Information Update: 29 May 2013
At a glance
- Drugs Forodesine (Primary)
- Indications Astrocytoma; Biliary cancer; Colorectal cancer; Gastric cancer; Haematological malignancies; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions
- 30 Jan 2008 Status changed from in progres to completed.
- 10 Sep 2005 New trial record.